Evaluating diverse technologies for detecting and validating senescent cells in vivo

评估用于检测和验证体内衰老细胞的多种技术

• 批准号: 10907053
• 负责人: Francesca E. Duncan
• 金额: $ 90.97万
• 依托单位: BUCK INSTITUTE FOR RESEARCH ON AGING
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10907053
• 关键词: Abdomen; Affect; Age; Aging; Antibodies; Aorta; Back; Biological; Biological Markers; Biological Models; Biology; Biopsy; Blood Vessels; Bystander Effect; CDKN2A gene; Cell Aging; Cell Culture Techniques; Cell Nucleus; Cell Proliferation; Cell surface; Cells; Characteristics; Chronology; Clinical; Communities; Complex; Data; Detection; Development; Disease; Doxorubicin; Elderly; Embryonic Development; Emerging Technologies; Explosion; Fatty acid glycerol esters; Frequencies; Gene Combinations; Gene Expression; Gene Expression Profiling; Genetic; Genetic Transcription; Genotype; Goals; Growth Factor; Human; Inflammatory; Injections; Lipids; Location; Mainstreaming; Malignant Neoplasms; Maps; Mass Spectrum Analysis; Measurable; Microbubbles; Microfluidics; Modeling; Molecular Profiling; Morphology; Mus; Muscle; Muscle Fibers; Nature; Nerve Degeneration; Ovarian; Ovarian Tissue; Ovarian aging; Ovary; Pathology; Peptide Hydrolases; Pharmaceutical Preparations; Phase; Phenotype; Physiological; Pilot Projects; Production; Protein Secretion; Research Personnel; Sensitivity and Specificity; Skeletal Muscle; Structure; Techniques; Technology; Therapeutic; Time; Tissues; Ultrasonography; Validation; Variant; Visualization; age related; aged; antibody conjugate; arteriole; biological adaptation to stress; biomarker identification; biomarker validation; cell type; chemokine; comparative; contrast enhanced; cytokine; design; digital; high risk; human subject; human tissue; improved; in vivo; innovative technologies; molecular marker; mouse model; nano-string; new technology; novel; prevent; protein expression; response; senescence; small molecule; transcriptomic profiling; ultrasound; whole genome

PROJECT SUMMARY Single cell profiling has recently exploded into mainstream biology. Single cell profiling has been employed in myriad applications in biology, including multiple diseases, embryonic development, comparative evolutionary studies and aging. Most recently, single cell profiling has informed the phenomena of cellular senescence. This proposal has two phases, UG3 (model systems), and UH3 (human validation). Cellular senescence is a multi-faceted cell fate that arrests cell proliferation, essentially irreversibly, and activates the production and secretion of pro-inflammatory cytokines, chemokines, growth factors, proteases and lipids, termed the Senescence Associated Secretory Phenotype (SASP). The SASP can influence tissue microenvironments, and thus senescent cells can strongly affect tissue function and likely the systemic milieu. Senescent cells increase with age and can drive a growing list of age-related pathologies, ranging from neurodegeneration to cancer, in part through the SASP. There is increasing evidence that there are no universal markers for senescent cells. Instead, senescent cells, while sharing certain characteristics and biomarkers, are remarkably heterogeneous, varying in characteristics with genotype, cell and tissue type, senescence inducer, tissue (and cell culture) microenvironment, and chronology (time after initial senescence induction). While some of the more commonly employed senescence markers have utility in superficially identifying senescent cells de novo, the onus remains on the investigator to demonstrate why a cell should be considered senescent, rather than relying on historical markers such as p16INK4a or p21Cip1. Thus, new technologies designed to identify novel senescent cells and phenotypes are necessary that will require validation both in culture and in tissue. The ultimate goal of this proposal is to develop new technologies to map senescent signatures back to intact human tissue. This goal will enable us to identify and spatially characterize senescent cells in each tissue, uncovering unique markers depending on tissue and cell type. Pilot 1: Identify senescent cells in the mouse vasculature, and determine if they can be detected by ultrasound, and verified in human tissue; Pilot 2: Develop a microphysiologic ex vivo tissue-on-a-chip to model ovarian senescence, and human tissue-tissue interactions via the SASP. These two pilots will use a combination of cell surface markers identified in our initial profiling, and Digital Spatial Profiling (DSP, Nanostring) or Visium (10x) to localize senescent signatures to morphological structures and cells in tissue sections. Our proposal will develop validated markers of senescence in multiple tissues and cell types not previously characterized to deploy these technologies to the broader community.

项目概要 单细胞分析最近已成为主流生物学。已采用单细胞分析 在生物学中的无数应用，包括多种疾病、胚胎发育、比较 进化研究和衰老。最近，单细胞分析揭示了细胞现象 衰老。该提案分为两个阶段：UG3（模型系统）和 UH3（人类验证）。 细胞衰老是一种多方面的细胞命运，它基本上不可逆转地阻止细胞增殖，并且 激活促炎细胞因子、趋化因子、生长因子、蛋白酶的产生和分泌 和脂质，称为衰老相关分泌表型（SASP）。 SASP 可以影响组织 微环境，因此衰老细胞可以强烈影响组织功能，并可能影响全身环境。 衰老细胞随着年龄的增长而增加，并可能导致越来越多的与年龄相关的病理，包括 神经退行性疾病导致癌症，部分是通过 SASP 实现的。 越来越多的证据表明，衰老细胞没有通用的标记。反而衰老了 细胞虽然具有某些特征和生物标志物，但具有显着的异质性，在 基因型、细胞和组织类型、衰老诱导物、组织（和细胞培养）的特征 微环境和时间顺序（初始衰老诱导后的时间）。 虽然一些更常用的衰老标记物可用于表面识别 衰老细胞从头开始，研究者有责任证明为什么应考虑细胞 衰老，而不是依赖 p16INK4a 或 p21Cip1 等历史标记。因此，新技术 旨在识别新的衰老细胞和表型是必要的，需要验证 在培养物和组织中。 该提案的最终目标是开发新技术将衰老特征映射回 完整的人体组织。这一目标将使我们能够识别和空间表征每个细胞中的衰老细胞。 组织，根据组织和细胞类型发现独特的标记。 试验 1：识别小鼠脉管系统中的衰老细胞，并确定它们是否可以通过以下方法检测到： 超声波，并在人体组织中得到验证；试点 2：开发微生理离体组织芯片来建模 卵巢衰老和通过 SASP 的人体组织间相互作用。 这两个试点将使用我们最初分析中确定的细胞表面标记物和数字技术的组合 空间分析（DSP、Nanostring）或 Visium (10x) 将衰老特征定位到形态结构 和组织切片中的细胞。我们的提案将开发多种组织中经过验证的衰老标记物 之前未表征的细胞类型无法将这些技术部署到更广泛的社区。